GenMont Biotech Incorporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 105.37 million compared to TWD 79.38 million a year ago. Net income was TWD 23.56 million compared to TWD 29.14 million a year ago. Basic earnings per share from continuing operations was TWD 0.27 compared to TWD 0.33 a year ago. Diluted earnings per share from continuing operations was TWD 0.27 compared to TWD 0.33 a year ago. Basic earnings per share was TWD 0.27 compared to TWD 0.33 a year ago. Diluted earnings per share was TWD 0.27 compared to TWD 0.33 a year ago. For the nine months, sales was TWD 308.61 million compared to TWD 238.35 million a year ago. Net income was TWD 68.91 million compared to TWD 53.21 million a year ago. Basic earnings per share from continuing operations was TWD 0.8 compared to TWD 0.6 a year ago. Diluted earnings per share from continuing operations was TWD 0.79 compared to TWD 0.6 a year ago. Basic earnings per share was TWD 0.8 compared to TWD 0.6 a year ago. Diluted earnings per share was TWD 0.79 compared to TWD 0.6 a year ago.